Podcasts about Medscape

Pink noise claims it can boost your memory, help your sleep, and treat your ADHD. But how it's studied in a sleep lab is very different from passive listening all night long. Chris and Sophie dive into the evidence to figure out if the influencers pushing pink noise for sleep got it right or if they're simply dreaming.   Become a supporter of our show today either on Patreon or through PayPal! Thank you! http://www.patreon.com/thebodyofevidence/ https://www.paypal.com/donate?hosted_button_id=9QZET78JZWCZE   Email us your questions at thebodyofevidence@gmail.com.   Editor:    Robyn Flynn Researcher: Danielle Kaprelian Theme music: “Fall of the Ocean Queen“ by Joseph Hackl Rod of Asclepius designed by Kamil J. Przybos Chris' book, Does Coffee Cause Cancer?: https://ecwpress.com/products/does-coffee-cause-cancer   Obviously, Chris is not your doctor (probably). This podcast is not medical advice for you; it is what we call information. References: The different colours of noise from white to pink to brown: https://www.allure.com/story/what-is-brown-noise-pink-white-sound-therapy The famous 2017 “memory enhancement” study: https://www.frontiersin.org/journals/human-neuroscience/articles/10.3389/fnhum.2017.00109/full A lay summary of the above study: https://time.com/collections/guide-to-sleep/4694555/pink-noise-deep-sleep-improve-memory/ The study showing pink noise might make things worse: https://academic.oup.com/sleep/article/49/5/zsag001/8452884 Dr. F. Perry Wilson's Medscape video series on pink noise: https://www.medscape.com/viewarticle/pink-noise-could-be-wrecking-your-sleep-2026a100039x A 2022 systematic review on overall sleep quality: https://pubmed.ncbi.nlm.nih.gov/34964434/ Memory claims and pink noise: https://www.frontiersin.org/journals/human-neuroscience/articles/10.3389/fnhum.2023.1302836/full Examples of white and pink noise are found here: https://en.wikipedia.org/wiki/File:Pink_noise.ogg and https://en.wikipedia.org/wiki/File:White-noise-sound-20sec-mono-44100Hz.ogg

Healthcare systems frequently treat women as a niche population, forcing them to navigate fragmented, episodic care models built on male physiology. What does it look like to genuinely operationalize a women-centric health system from the front lines? This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities.

Photo by CDC on Unsplash Pediatric providers — whether a pediatrician or pediatric nurse practitioner—are in short supply not just here but across the country. One pediatric nurse practitioner is sounding the alarm about this issue and HealthCetera producer and host, Diana Mason, RN, PhD, talked with this nurse, Dr. Rajashree Koppolu, about the shortage, its impact on access to care for children and their families, and what can be done to address the issue. Dr. Koppolu serves as Manager of Advanced Practice Professional Development for Stanford Medicine Children’s Health and has held advanced clinical roles in pediatric general surgery and cardiology as a pediatric nurse practitioner. She is a past president of the National Association of Pediatric Nurse Practitioners (NAPNAP) and is a Fellow of the American Academy of Nursing. She's also a Senior Fellow at the Center for Health Policy and Media Engagement at the GWU School of Nursing. In February 2026, she published an article for Medscape titled “Growing Shortage of Pediatric Healthcare Workforce.” This interview first aired on HealthCetera in the Catskills on WIOX Radio on April 15, 2026. The post Pediatric Provider Shortage appeared first on HealthCetera.

40% of doctors have a side gig — and most are one contract clause away from handing it to their employer. Forty percent of physicians now run a side gig — chart reviews, expert witness work, SaaS tools, real estate, content, consulting. But here's what nobody covered in residency: most are leaving money on the table at tax time, mixing business and personal finances into an unfixable mess, or unknowingly signing away their intellectual property in an employment contract they barely skimmed. In this episode of Money Meets Medicine, Dr. Jimmy Turner and CFP Justin Harvey unpack what physicians actually need to know before they earn their first non-clinical dollar — and what to do once they're already five figures a month in. If you've ever wondered whether you should be an S Corp, whether your hospital can claim your nights-and-weekends project, or whether business ownership is even worth the headache, this one is for you. Resources: Need a new CPA? Work with Gelt, the proactive tax strategy partner that Jimmy uses, and receive 10% off the first year through the MMM link — https://moneymeetsmedicine.com/CPA Disability Insurance — Where physicians (especially trainees) can request a GSI quote and learn whether one is available at their program — moneymeetsmedicine.com/disability Medscape 2025 Physician Side Gig Survey - https://www.medscape.com/slideshow/doctors-side-gigs-2025-6018502   Episode Summary An orthopedic surgeon writes in: he's pulling $550K at an academic center and has quietly built an AI-powered prior authorization SaaS now generating five figures a month. What should he be thinking about? Jimmy and Justin use that question as a launchpad into the financial reality of physician non-clinical income — the ups, the downs, and the surprisingly counterintuitive parts. Jimmy, recently transitioned from 15 years as a W-2 academic anesthesiologist to a 1099 private practice gig, shares why business ownership has been more stressful than running codes — and why he's still glad he did it. He explains why a $30,000 surprise tax bill finally pushed him to bring in a real tax strategy team (not the February-only compliance CPA most physicians settle for), and the difference between the two. The conversation digs into the Medscape 2025 numbers: 40% of physicians have a side gig, 50% between ages 40 and 50, and 60% say they're doing it for extra income. Most physicians aren't actually trying to leave medicine — they're trying to build enough financial freedom to practice on their own terms. Sometimes a $60,000 side income buys back a day of the week. Justin pushes on the harder questions: What's your goal? What's the actual ROI once you factor in CPA fees, self-employment tax, and the brain space business ownership demands? Why some physicians thrive in 1099-land and others should sprint back to W-2. They also walk through the practical setup — the deceptively simple three-step LLC-EIN-bank-account process most physicians overcomplicate or skip entirely — and the contract landmine almost no academic physician thinks about: who actually owns the work you do on nights and weekends. Plus the tax-strategy doors most W-2 doctors don't realize are closed to them: S Corp elections, QBI, solo 401(k)s, cash balance plans, and pass-through entity tax. If you're already running a side gig or seriously thinking about one, this is the cheat sheet you wish someone had handed you before you started. What You'll Learn Why 40% of physicians now run a side gig — and the real reason most start one (it's not what you think) The three-step business setup most physicians overcomplicate: LLC, EIN, separate bank account How an employment contract clause can quietly hand your side gig over to your hospital — and how to negotiate it before you sign When a tax strategy team actually pays for itself versus when basic compliance is enough The ROI math on 1099 income: what your side gig really needs to clear after self-employment tax, professional fees, and added complexity Side gigs with lower ceilings but much higher odds of success — and why 90% of online businesses fail Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The U.S. preterm birth rate has seen double-digit growth over the last decade, reaching a staggering 10.4%. Join Zhenya Lindgardt, CEO of Sera Prognostics, and Dr. Mollie McDonnold as they discuss how breakthrough biomarkers and a "preventive bundle" are finally offering a way to move the needle in the right direction. This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities.

Send us Fan MailIs American healthcare collapsing?In this clip from our episode "How AI Could Save a Collapsing Healthcare System," host David E. Williams and Dr. Robert Pearl, Author of ChatGPT MD, break down why the current system is financially unsustainable and why physicians have never had the tools to fight back. Until now.Listen to the full episode here

This week's episode reviews the findings published in Medscape's Physician Compensation Report for 2026. Key PointsThe Numbers: The average physician salary rose to $356K (+3%), with Specialists ($417K) continuing to outearn PCPs ($298K).Top Earners: Orthopedics leads the field at $611K, followed by Cardiology ($575K) and Radiology ($571K); Pediatrics remains at the bottom ($266K).The Negotiation Freeze: 27% of physicians reported negotiation wasn't an option, as some consultants now advise employers to adopt a "no-negotiation" philosophy to maintain workplace equity.Demographic Gaps: Significant disparities persist, including a 31% gender pay gap and slower compensation growth for Black (2.9%) and Hispanic (3.5%) physicians compared to their White peers (6.1%).Productivity & Hours: The average work week dipped to 49 hours, yet 35% of doctors now see their base salary—not just bonuses—tied directly to productivity metrics like RVUs.https://www.medscape.com/p11/return-normalization-medscape-physician-compensation-report-2026a10009umPlease subscribe and leave a review on your favorite Podcasting platform. Get 12 Financial Mistakes that Keep Physicians from Building Wealth at https://www.growyourwealthymindset.com/12financialmistakesIf you want to start your path to financial freedom, start with the Financial Freedom Workbook. Download your free copy today at https://www.GrowYourWealthyMindset.com/fiworkbookDr. Elisa Chiang is  a physician and money coach who helps other doctors reach their financial goals by mastering their money mindset through personalized 1:1 coaching .You can learn more about Elisa at her website or follow her on social media.Website: https://ww.GrowYourWealthyMindset.comInstagram https://www.instagram.com/GrowYourWealthyMindsetFacebook https://www.facebook.com/ElisaChianghttps://www.facebook.com/GrowYourWealthyMindsetYouTube: https://www.youtube.com/c/WealthyMindsetMDLinked In: www.linkedin.com/in/ElisaChiang Disclaimer: The content provided in the Grow Your Wealthy Mindset Podcast...

The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects.  Features Dr. Jack Cush, Editor at RheumNow.com. Show Notes: Chinese target emulation trial of MDA-5+, dermatomyositis w/ ILD. 106 Rx w/ UPA & 328 w/ TOFA. 6-month lung transplantation-free survival 72% vs 67% (UPA v TOFA). UPA non-inferior to TOFA in MDA5+DM-ILD https://t.co/BBAfbM06AM In 2025 DTC TV ad spending by top 10 incr to $2.67 billion (up from $2.1 B). Rheum Drugs in top 3: 1. Skyrizi $440 million 2. Tremfya $431 M 3. Rinvoq $376 M https://t.co/EsWgUqUy9Z 2. Dermatology Salaries 2025 – Dermatology is top 10 at $448K according to Medscape; expected to go down -1% in 2026; derms made up 2% of survey group 37K MDs 3. Itch is common in Scleroderma (SSc) and not related to Dz duration. Study of 2173 Pts (~20K itch assessments), 87 F; mean age 55 yrs; 40% w/ diffuse SSc. Itch (moderate 4/10) seen in ~35% at all times https://t.co/QnT8d0xA5Z 4. Asia-Pacific Lupus study of Mucocutaneous activity (MC-A) in 4102 SLE pts. 36% had MC-A (rash 1055; alopecia 731; m ulcers 352); 15% persistently. MC-A assoc w/ W, smoking, +serologies, vasculitis, myositis, serositis, nephritis, NP-SLE https://buff.ly/D5fXJdY 5. Predictors of Calcinosis Cutis in Systemic Sclerosis   6. AFFINITY Study - Combination Biologic Therapy in PsA A pilot trial assessed the efficacy and safety of the guselkumab+golimumab (COMBO) combination versus GUS monotherapy in active PsA (failing a prior tumor necrosis factor inhibitor (TNFi-IR) and showed superiority in ACR 50 https://t.co/f2CB8FnZMB 7. AAD 2026 Annual Mtg presents new data on another TYK2 inhibitor. In 2 phase 3 RCTs (ONWARD1 ONWARD2) envudeucitinib was superior to placebo & apremilast in 1700 plaque psoriasis pts https://t.co/DPlzDw5m7N 8. Among 1074 #PsA tested annually, RF positivity was found in 16.1% overall (5.1% RF+ at baseline). RF+ rediced odds of MDA (OR 0.53) w/ incr risk of bDMARD discontinuation (OR 2.65) https://buff.ly/BsM7NKQ 9. The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis - Review 10. Ixekizumab With Tirzepatide Efficacy in Obese Psoriatic Arthritis 11. Brepocitinib in Dermatomyositis

Send us Fan MailAmerican employers now spend over $25,000 a year to cover a single family, and chronic disease is driving the system toward collapse. Yet medicine is still built around a doctor's office visit every three to four months.Dr. Robert Pearl, former CEO of the Permanente Medical Group, Stanford professor, and author of ChatGPT MD, joins host David E. Williams to make the case that generative AI is the only tool that can shift medicine from episodic to continuous care, and why without it, the chronic disease crisis will break American healthcare entirely.

Can a chance meeting in a hospital stairwell change the course of a career? Dr. Toyin Nwafor and Dr. Shirin Mazumder discuss how 20 years of mentorship and shared purpose in HIV medicine transformed their lives. This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities.

Dr. Diana Londoño, a board-certified urologist, will explore the powerful connection between emotional states and physical health, emphasizing how our inner experiences directly influence disease and healing. She will explain how the nervous system responds differently to fear and love—fear activating stress pathways that can weaken immunity and contribute to chronic illness, while love and safety promote balance, repair, and overall well-being. By contrasting the physiological and psychological impacts of fear versus love, she highlights how our emotional patterns can either harm or support our health. Central to her discussion is the idea that gratitude serves as a transformative bridge, fostering abundance, deeper human connection, and improved health by shifting the body and mind into a more resilient and harmonious state. Show Highlights · Dr. James JC Cooley along with Co-Host Dr. Michael Mantell- renowned and esteemed mental health architect and prolific author have a sit-down conversation with Dr. Diana Londoño - Board-Certified Urologist and International Speaker and guest on multiple podcasts. · How Your Emotions Shape Your Health and Nervous System · Rewiring the Nervous System Through Love and Gratitude · Gratitude as Medicine: Bridging Emotion, Nervous System, and Well-Being Dr. Diana Londoño Biography Dr. Diana Londoño is a Board-Certified Urologist and one of the 12% of urologists in the US who are women and the 0.5% who are Latinx and women. She is originally from Mexico City, attended Claremont McKenna College for her undergraduate studies, and then went on to UCLA for medical school. She completed a 6-year residency in Urology at Kaiser Permanente in Los Angeles.She is an international speaker and guest on multiple podcasts, discussing topics including wellness, humanity in medicine, mindset, and urology. She has also appeared on Univision, Telemundo, Mundo Fox, CNN Latino, and KCET, and has been published in Kevin MD, Medscape, WebMD, and Men’s Health. She is a contributing author to books on burnout and heart-centered leadership. She focuses on understanding and integrating the power of emotions as they interplay in our disease or wellness. She believes love should be the foundation and at the forefront of healthcare and our personal health, and that when we integrate and align our physical, emotional, spiritual, and energetic facets, we can attain true healing. She is a Reiki Master and a Certified Pranic (Energy) Healer and the mother of two determined and joyful 7 and 10-year-old girls, Daniela and Paloma. Websites/Social MediaDr. Diana Londoño - Urology, Prostate, Kidney Stones (dianalondonomd.com) Diana (Thorne) Londoño, MD | LinkedIn Diana Londoño, MD. Urologist, Life Coach. (@dianalondonomd) • Instagram photos and videos https://www.youtube.com/@dianalondonomdSupport the show: http://www.cooleyfoundation.org/See omnystudio.com/listener for privacy information.

In this episode of Hear From Her, we dive into the essential role of mentorship in advancing women's careers within healthcare. From navigating "bulldog" leadership styles to overcoming imposter syndrome, our guests share personal stories of how intentional professional alliances helped them ascend to executive roles. We explore the difference between formal and informal networks, the necessity of embracing "messy" innovation, and why every woman needs a "strategic advisory board" for her life. This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities.

What happens when you stop treating patients and start partnering with them? Dr. Doreen Addrizzo-Harris and Dr. Martina Flammer join us to discuss the "infectious" power of care networks, the bravery required to pivot in your career, and why optimism is a strategic tool for the modern medical leader. This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities

Why is a "linear" career path becoming a thing of the past? Join Giulia Ghibellini and Professor Amanda Kirby as they share how personal challenges with neurodiversity transformed their professional missions. Discover why the most impactful leaders aren't the ones who avoided struggles, but the ones who harnessed them to build more inclusive industries. This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities.

From the stages of Egypt to the global C-suite, Dr. Lobna Salem (CMO, Viatris) has always led with a "quiet courage". Join her and world-renowned pharmaceutical executive Dr. Amrit Ray as they discuss why the most effective leaders aren't just experts in their field—they are experts in humanity. This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities.

How much do physicians actually need to retire comfortably? If you've heard numbers like $4 million—or more—and felt overwhelmed, you're not alone.In this episode, we break down where these retirement numbers come from, why physicians tend to think they need significantly more than the average American, and how to calculate a retirement target that actually fits your life.Using data from Medscape, Northwestern Mutual, and the U.S. Census Bureau, we explore income differences, spending expectations, taxes, and the realities of retiring as a physician, especially if you're considering early retirement.What You'll Learn in This Episode:What physicians report needing for retirement and how that compares to the average AmericanWhy higher income doesn't automatically mean you need more to retireHow delayed earnings and fewer high-income years affect physician retirement planningWhy retirement planning is really about spending, not just net worthHow taxes change your true retirement numberThe role of lifestyle choices and flexibility in determining how much is “enough”What to consider if you want to retire before age 60, including healthcare costsA better question to ask instead of “What's my retirement number?”Key Takeaway:There is no single “right” retirement number for physicians. Your retirement target depends on your spending, lifestyle goals, taxes, and timeline—not what other doctors are doing.Please subscribe and leave a review on your favorite Podcasting platform. Get 12 Financial Mistakes that Keep Physicians from Building Wealth at https://www.growyourwealthymindset.com/12financialmistakes If you want to start your path to financial freedom, start with the Financial Freedom Workbook. Download your free copy today at https://www.GrowYourWealthyMindset.com/fiworkbook Dr. Elisa Chiang is a physician and money coach who helps other doctors reach their financial goals by mastering their money mindset through personalized 1:1 coaching . You can learn more about Elisa at her website or follow her on social media. Website: https://ww.GrowYourWealthyMindset.com Instagram https://www.instagram.com/GrowYourWealthyMindset Facebook https://www.facebook.com/ElisaChiang https://www.facebook.com/GrowYourWealthyMindset YouTube: https://www.youtube.com/c/WealthyMindsetMD Linked In: www.linkedin.com/in/ElisaChiang Disclaimer: The content provided in the Grow Your Wealthy Mind...

This episode dives into the often-overlooked intersection of hepatology and women's health. Tatyana Kushner and Andrea Goldstein share their professional journeys, from the high-intensity liver transplant units of UCLA to pioneering women's liver health programs and their personal connections to the field. The conversation focuses on the complexities of Intrahepatic Cholestasis of Pregnancy (ICP) and Primary Biliary Cholingitis (PBC), highlighting the racial disparities in diagnosis and the critical need for genetic testing. Our guests discuss the challenges of clinical trials in pregnant populations and offer a roadmap for better preconception counseling, interdisciplinary care, and the power of patient advocacy.  Adding a deeply personal perspective, the host also shares her own experience with ICP, underscoring why early recognition and coordinated care are essential for protecting both maternal and fetal health. This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities.

Think sleep apnea is just for "middle-aged men who snore?" Think again. Dr. Kimberly Sterling and Dr. Audrey Wells join us to reveal why 90% of women are living with undiagnosed sleep apnea and how "invisible" symptoms like fatigue and anxiety are masking a life-threatening breathing disorder. This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities.

Join Lindsay Davies, CEO of QVance, and Angela Vollstedt, Global Director of R&D at Novartis, as they discuss why innovation in medicine requires the courage to embrace ambiguity. We explore how women are redefining leadership by moving beyond corporate "precision" to master the art of being an intrapreneur. This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities.

The endocrine system consists of eight major organs that produce and regulate hormones, the chemical messengers that keep the body in balance. Hormones quietly orchestrate everything from our energy and metabolism to mood, sleep, and resilience, acting as an internal communication network that responds to stress, environment, and lifestyle. From cold plunges and saunas to endocrine-disrupting chemicals, even small daily inputs are said to shift this delicate signaling. How does stress really affect our bodies? Does “adrenal fatigue” exist? Is it actually possible to “biohack” our hormones?In this episode, we are joined by Dr. Priya Jaisinghani, MD, ABIM, DABOM, a triple board-certified Endocrinology, Obesity Medicine, and Internal Medicine physician from New York City.Dr. Jaisinghani received her MD from Rutgers/Robert Wood Johnson Medical School, where she also completed her Internal Medicine Residency, Endocrinology and Obesity Medicine Fellowships at Weill Cornell Medicine. Currently, Dr. Jaisinghani is a Diabetes, Metabolism, and Obesity Medicine attending physician at NYU Langone Health, Clinical Assistant Professor of Medicine at NYU Grossman School of Medicine, and a Medical Unit Contributor at ABC News.Dr. Jaisinghani has been featured on CNN, Rolling Stone, The New York Times, The Wall Street Journal, Men's Health, FOX 5 News, and Medscape,Follow Friends of Franz Podcast: Website, Instagram, FacebookFollow Christian Franz (Host): Instagram, YouTube

Leaders Dr Nieca Goldberg and Dr Maria Emanuel Ryan dismantle the traditional "silos" of healthcare to reveal how oral health directly impacts cardiovascular wellness. Drawing from their shared history as Barnard College alumni and their respective expertise in cardiology and periodontics, they discuss the systemic inflammation that links gum disease to heart health. The conversation dives into the unique physiological challenges women face during puberty, pregnancy, and menopause, highlighting how hormonal shifts influence total body health. Walk away with a stronger understanding of how to advocate for your own health and why "total body care" is more than just a buzzword. This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities.

Welcome to PsychEd, the psychiatry podcast for medical learners, by medical learners. This short episode covers Types of SubstancesHosts: Sara Abrahamson, Shaoyuan Wang and Kate Braithwaite.Audio Editing: Kate BraithwaiteReferences:American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5, text revision (DSM-5-TR). 5th ed. Washington, D.C.: American Psychiatric Association Publishing; 2022.CAMH. (2013). Inhalants. Inhalants | CAMHCAMH. (2010). Cocaine and Crack. https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/cocaineCAMH. (2012). Amphetamines. https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/amphetamines#:~:text=Chronic%20use%20of%20amphetamines%20can,can%20also%20cause%20amphetamine%20psychosis.Chae J, Marsden J and Sutherland A. (2024, August 21). Benzodiazepine Withdrawal. Emergency Care BC. Benzodiazepine Withdrawal : Emergency Care BCChildHealthBC. (2023, September 21). Common Street names for Substances. https://childhealthbc.ca/mhsu/common_streetnames_substances/printfileJauch EC. (2023, January 18) Inhalants Clinical Presentation. Medscape. Inhalants Clinical Presentation: History, Physical, CausesKaye, AD, Staser, AN, Mccollins, TS, Zheng, J, Berry, FA, Burroughs, CR, Heisler, M, Mouhaffel, A, Ahmadzadeh, S, Kaye, AM, Shekoohi, S, & Varrassi, G. (2024). Delirium Tremens: A Review of Clinical Studies. Cureus, 16(4), e57601. https://doi.org/10.7759/cureus.57601Long N. (2020, November 3). GHB toxicity. Life in the Fast Lane. GHB toxicity • LITFL • Toxicology Library ToxicantMedx. (2025, November 26). Understanding What is the MOA of Alcohol: A Pharmacological Perspective. What is the MOA of Alcohol? Explained: Receptors and EffectsMendelson, J. H., & Mello, N. K. (1996). Management of cocaine abuse and dependence. The New England journal of medicine, 334(15), 965–972. https://doi.org/10.1056/NEJM199604113341507Nichols DE. Hallucinogens. Pharmacol Ther. 2004 Feb;101(2):131-81. doi: 10.1016/j.pharmthera.2003.11.002.Nickson C. (2024, December 18). Sedative toxidrome. Life in the Fast Lane. Sedative Toxidrome • LITFL • CCC ToxicologyPorter RS, Kaplan JL, Homeier BP, editors. The Merck manual of diagnosis and therapy. 20th ed. Kenilworth (NJ): Merck Sharp & Dohme; 2018.PsychDB. (2021, March). Opioid Intoxication. Opioid Intoxication - PsychDBPsychDB. (2023, October). Opioid Withdrawal. Opioid Withdrawal - PsychDBPsychDB. (2023 February). Cannabis Withdrawal. Cannabis Withdrawal - PsychDBRoth BL, Gumpper RH. Psychedelics as Transformative Therapeutics. Am J Psychiatry. 2023 May 1;180(5):317-20.Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci. 2010 Sep;11(9):642-51. doi: 10.1038/nrn2884.

Drs Joseph Mikhael and Shaji Kumar discuss the future of multiple myeloma, including enhanced diagnostics for detecting myeloma, frontline therapy, and durable responses. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002718. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Multiple Myeloma https://emedicine.medscape.com/article/204369-overview Updated Diagnostic Criteria and Staging System for Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/27249749/ Mass Spectrometry for the Evaluation of Monoclonal Proteins in Multiple Myeloma and Related Disorders: An International Myeloma Working Group Mass Spectrometry Committee Report https://pubmed.ncbi.nlm.nih.gov/33563895/ Multiple Myeloma Imaging https://emedicine.medscape.com/article/391742-overview Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis https://pubmed.ncbi.nlm.nih.gov/34299097/ Monoclonal Gammopathy of Undetermined Significance https://www.ncbi.nlm.nih.gov/books/NBK507880/ Primary Plasma Cell Leukemia: Consensus Definition by the International Myeloma Working Group According to Peripheral Blood Plasma Cell Percentage https://pubmed.ncbi.nlm.nih.gov/34857730/ Advancing MRD Detection in Multiple Myeloma: Technologies, Applications, and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/40214184/ Genomic Landscape of Multiple Myeloma and Its Precursor Conditions https://pubmed.ncbi.nlm.nih.gov/40399554/  Quadruplet Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/39348665/ Subcutaneous Daratumumab (Dara) + Bortezomib/Lenalidomide/Dexamethasone (VRd) With Dara + Lenalidomide (DR) Maintenance in Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Sustained Minimal Residual Disease Negativity in the Phase 3 PERSEUS Trial https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.7501 Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial https://pubmed.ncbi.nlm.nih.gov/39841461/ Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant Is Not a Medically Suitable Treatment https://www.clinicaltrials.gov/study/NCT05561387 Cytokine Release Syndrome and Associated Neurotoxicity in Cancer Immunotherapy https://pubmed.ncbi.nlm.nih.gov/34002066/ The Role of CELMoD Agents in Multiple Myeloma https://pmc.ncbi.nlm.nih.gov/articles/PMC12399888/ Phase 2 Study of Talquetamab + Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma and Extramedullary Disease: REDIRECTT-1 https://library.ehaweb.org/eha/2025/eha2025-congress/4173809/shaji.kumar.phase.2.study.of.talquetamab.2B.teclistamab.in.patients.with.html Discovery of a Novel Class NSD2 Inhibitor for Multiple Myeloma With t(4;14) https://pubmed.ncbi.nlm.nih.gov/40949769/ Long-Term (≥5 Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel (Cilta-Cel) in CARTITUDE-1 Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.7507

Schizophrenia is a mental disorder characterised by impairments in the way reality is perceived with associated changes in behaviour. We cover the symptoms of Schizophrenia (with delusion types), including the DSM-5 criteria for diagnosis, as well as Schizophrenia treatment. PDFs available here: https://rhesusmedicine.com/pages/psychiatryConsider subscribing (if you found any of the info useful!): https://www.youtube.com/channel/UCRks8wB6vgz0E7buP0L_5RQ?sub_confirmation=1Patreon: https://www.patreon.com/rhesusmedicineBuy Us A Coffee!: https://www.buymeacoffee.com/rhesusmedicineTimestamps:0:00 What is Schizophrenia?0:28 Schizophrenia Symptoms - Positive Symptoms2:28 Schizophrenia Symptoms - Negative Symptoms2:58 Schizophrenia Symptoms - Cognitive Symptoms 3:49 Schizophrenia Diagnosis / Diagnostic DSM 5 Criteria 5:08 Schizophrenia Causes / Pathophysiology 5:53 Schizophrenia Risk Factors & Epidemiology 7:00 Schizophrenia Treatment LINK TO SOCIAL MEDIA: https://www.instagram.com/rhesusmedicine/ReferencesNational Institute of Mental Health (NIMH), 2025. Schizophrenia. [online] Available at: https://www.nimh.nih.gov/health/topics/schizophrenia.World Health Organization (WHO), 2025. Schizophrenia. [online] Available at: https://www.who.int/news-room/fact-sheets/detail/schizophrenia.National Alliance on Mental Illness (NAMI), 2025. Schizophrenia. [online] Available at: https://nami.org/About-Mental-Illness/Mental-Health-Conditions/Schizophrenia.Wikipedia, 2025. Schizophrenia. [online] Available at: https://en.wikipedia.org/wiki/Schizophrenia.Medscape, 2025. Schizophrenia: Symptoms, Causes & Treatment Options. [online] Available at: https://emedicine.medscape.com/article/288259-overview.Symptom Media, 2025. Schizophrenia Delusions: Definition, Types, and Treatments. [online] Available at: https://symptommedia.com/delusions-associated-with-schizophrenia-ce-course-preview/.Psycom, 2025. Schizophrenia: Symptoms, Causes, Diagnosis, Treatment. [online] Available at: https://www.psycom.net/schizophrenia.StatPearls, 2025. Schizophrenia. [online] Available at: https://www.ncbi.nlm.nih.gov/books/NBK539864/.Disclaimer: Please remember this podcast and all content from Rhesus Medicine is for educational and entertainment purposes only and is not a guide to diagnose or to treat any form of condition. The content is not to be used to guide clinical practice and is not medical advice. Please consult a healthcare professional for medical advice.

Dr. Dara Kass shares the origin story of FemInEM, her organization born from a need for collective action to neutralize biases women face in medicine, such as advocating for maternity leave and salary transparency. She recounts her pivotal time in the US Department of Health and Human Services, which revealed the brokenness of the system beyond healthcare delivery itself. Today, Dr. Kass is tackling the post-Dobbs landscape with a strategic focus on empowering emergency physicians to deliver legal and safe reproductive healthcare through evidence-based protocols and education. Crucially, she discusses the necessity of funding this crucial advocacy work, ensuring that women are paid for their passion and not simply giving their time away for free. This conversation is a compelling call to action for every physician to find their focus, build their community, and maintain hope in the face of overwhelming challenges. This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities.

This episode explores the rapidly advancing field of neuromodulation, where targeted magnetic and electrical stimulation techniques are transforming the way we understand and treat brain disorders. Host Dr. Jovana Lubarda speaks with Dr. Carolyn Rodriguez and Dr. Colleen Hanlon about transcranial magnetic stimulation (TMS) and its expanding role as a non-invasive, circuit-based therapy reshaping psychiatric and neurological care. This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities.

Dr. Linda Duska and Dr. Kathleen Moore discuss key studies in the evolving controversy over radical upfront surgery versus neoadjuvant chemotherapy in advanced ovarian cancer. TRANSCRIPT Dr. Linda Duska: Hello, and welcome to the ASCO Daily News Podcast. I am your guest host, Dr. Linda Duska. I am a professor of obstetrics and gynecology at the University of Virginia School of Medicine.  On today's episode, we will explore the management of advanced ovarian cancer, specifically with respect to a question that has really stirred some controversy over time, going all the way back more than 20 years: Should we be doing radical upfront surgery in advanced ovarian cancer, or should we be doing neoadjuvant chemotherapy? So, there was a lot of hype about the TRUST study, also called ENGOT ov33/AGO-OVAR OP7, a Phase 3 randomized study that compares upfront surgery with neoadjuvant chemotherapy followed by interval surgery. So, I want to talk about that study today. And joining me for the discussion is Dr. Kathleen Moore, a professor also of obstetrics and gynecology at the University of Oklahoma and the deputy director of the Stephenson Cancer Center, also at the University of Oklahoma Health Sciences.  Dr. Moore, it is so great to be speaking with you today. Thanks for doing this. Dr. Kathleen Moore: Yeah, it's fun to be here. This is going to be fun. Dr. Linda Duska: FYI for our listeners, both of our full disclosures are available in the transcript of this episode.  So let's just jump right in. We already alluded to the fact that the TRUST study addresses a question we have been grappling with in our field. Here's the thing, we have four prior randomized trials on this exact same topic. So, share with me why we needed another one and what maybe was different about this one? Dr. Kathleen Moore: That is, I think, the key question. So we have to level-set kind of our history. Let's start with, why is this even a question? Like, why are we even talking about this today? When we are taking care of a patient with newly diagnosed ovarian cancer, the aim of surgery in advanced ovarian cancer ideally is to prolong a patient's likelihood of disease-free survival, or if you want to use the term "remission," you can use the term "remission." And I think we can all agree that our objective is to improve overall survival in a way that also does not compromise her quality of life through surgical complications, which can have a big effect. The standard for many decades, certainly my entire career, which is now over 20 years, has been to pursue what we call primary cytoreductive surgery, meaning you get a diagnosis and we go right to the operating room with a goal of achieving what we call "no gross residual." That is very different – in the olden days, you would say "optimal" and get down to some predefined small amount of tumor. Now, the goal is you remove everything you can see.  The alternative strategy to that is neoadjuvant chemotherapy followed by interval cytoreductive surgery, and that has been the, quote-unquote, "safer" route because you chemically cytoreduce the cancer, and so, the resulting surgery, I will tell you, is not necessarily easy at all. It can still be very radical surgeries, but they tend to be less radical, less need for bowel resections, splenectomy, radical procedures, and in a short-term look, would be considered safer from a postoperative consideration. Dr. Linda Duska: Well, and also maybe more likely to be successful, right? Because there's less disease, maybe, theoretically. Dr. Kathleen Moore: More likely to be successful in getting to no gross residual. Dr. Linda Duska: Right. Yeah, exactly. Dr. Kathleen Moore: I agree with that. And so, so if the end game, regardless of timing, is you get to no gross residual and you help a patient and there's no difference in overall survival, then it's a no-brainer. We would not be having this conversation. But there remains a question around, while it may be more likely to get to no gross residual, it may be, and I think we can all agree, a less radical, safer surgery, do you lose survival in the long term by this approach? This has become an increasing concern because of the increase in rates of use of neoadjuvant, not only in this country, but abroad. And so, you mentioned the four prior studies. We will not be able to go through them completely. Dr. Linda Duska: Let's talk about the two modern ones, the two from 2020 because neither one of them showed a difference in overall survival, which I think we can agree is, at the end of the day, yes, PFS would be great, but OS is what we're looking for. Dr. Kathleen Moore: OS is definitely what we're looking for. I do think a marked improvement in PFS, like a real prolongation in disease-free survival, for me would be also enough. A modest improvement does not really cut it, but if you are really, really prolonging PFS, you should see that-  Dr. Linda Duska: -manifest in OS. Dr. Kathleen Moore: Yeah, yeah. Okay. So let's talk about the two modern ones. The older ones are EORTC and CHORUS, which I think we've talked about. The two more modern ones are SCORPION and JCOG0602. So, SCORPION was interesting. SCORPION was a very small study, though. So one could say it's underpowered. 170 patients. And they looked at only patients that were incredibly high risk. So, they had to have a Fagotti score, I believe, of over 9, but they were not looking at just low volume disease. Like, those patients were not enrolled in SCORPION. It was patients where you really were questioning, "Should I go to the OR or should I do neoadjuvant? Like, what's the better thing?" It is easy when it's low volume. You're like, "We're going." These were the patients who were like, "Hm, you know, what should I do?" High volume. Patients were young, about 55. The criticism of the older studies, there are many criticisms, but one of them is that, the criticism that is lobbied is that they did not really try. Whatever surgery you got, they did not really try with median operative times of 180 minutes for primary cytoreduction, 120 for neoadjuvant. Like, you and I both know, if you're in a big primary debulking, you're there all day. It's 6 hours. Dr. Linda Duska: Right, and there was no quality control for those studies, either. Dr. Kathleen Moore: No quality control. So, SCORPION, they went 451-minute median for surgery. Like, they really went for it versus four hours and then 253 for the interval, 4 hours. They really went for it on both arms. Complete gross resection was achieved in 50% of the primary cytoreduced. So even though they went for it with these very long surgeries, they only got to the goal half the time. It was almost 80% in the interval group. So they were more successful there. And there was absolutely no difference in PFS or OS. They were right about 15 months PFS, right about 40 months OS.  JCOG0602, of course, done in Japan, a big study, 300 patients, a little bit older population. Surprisingly more stage IV disease in this study than were in SCORPION. SCORPION did not have a lot of stage IV, despite being very bulky tumors. So a third of patients were stage IV. They also had relatively shorter operative times, I would say, 240 minutes for primary, 302 for interval. So still kind of short. Complete gross resection was not achieved very often. 30% of primary cytoreduction. That is not acceptable. Dr. Linda Duska: Well, so let's talk about TRUST. What was different about TRUST? Why was this an important study for us to see? Dr. Kathleen Moore: So the criticism of all of these, and I am not trying to throw shade at anyone, but the criticism of all of these is if you are putting surgery to the test, you are putting the surgeon to the test. And you are assuming that all surgeons are trained equally and are willing to do what it takes to get someone to no gross residual. Dr. Linda Duska: And are in a center that can support the post-op care for those patients. Dr. Kathleen Moore: Which can be ICU care, prolonged time. Absolutely. So when you just open these broadly, you're assuming everyone has the surgical skills and is comfortable doing that and has backup. Everybody has an ICU. Everyone has a blood bank, and you are willing to do that. And that assumption could be wrong. And so what TRUST said is, "Okay, we are only going to open this at centers that have shown they can achieve a certain level of primary cytoreduction to no gross residual disease." And so there was quality criteria. It was based on – it was mostly a European study – so ESGO criteria were used to only allow certified centers to participate. They had to have a surgical volume of over 36 cytoreductive surgeries per year. So you could not be a low volume surgeon. Your complete resection rates that were reported had to be greater than 50% in the upfront setting. I told you on the JCOG, it was 30%. Dr. Linda Duska: Right. So these were the best of the best. This was the best possible surgical situation you could put these patients in, right? Dr. Kathleen Moore: Absolutely. And you support all the things so you could mitigate postoperative complications as well. Dr. Linda Duska: So we are asking the question now again in the ideal situation, right? Dr. Kathleen Moore: Right. Dr. Linda Duska: Which, we can talk about, may or may not be generalizable to real life, but that's a separate issue because we certainly don't have those conditions everywhere where people get cared for with ovarian cancer. But how would you interpret the results of this study? Did it show us anything different? Dr. Kathleen Moore: I am going to say how we should interpret it and then what I am thinking about. It is a negative study. It was designed to show improvement in overall survival in these ideal settings in patients with FIGO stage IIIB and C, they excluded A, these low volume tumors that should absolutely be getting surgery. So FIGO stage IIIB and C and IVA and B that were fit enough to undergo radical surgery randomized to primary cytoreduction or neoadjuvant with interval, and were all given the correct chemo. Dr. Linda Duska: And they were allowed bevacizumab and PARP, also. They could have bevacizumab and PARP. Dr. Kathleen Moore: They were allowed bevacizumab and PARP. Not many of them got PARP, but it was distributed equally, so that would not be a confounder. And so that was important. Overall survival is the endpoint. It was a big study. You know, it was almost 600 patients. So appropriately powered. So let's look at what they reported. When they looked at the patients who were enrolled, this is a large study, almost 600 patients, 345 in the primary cytoreductive arm and 343 in the neoadjuvant arm. Complete resection in these patients was 70% in the primary cytoreductive arm and 85% in the neoadjuvant arm. So in both arms, it was very high. So your selection of site and surgeon worked. You got people to their optimal outcome. So that is very different than any other study that has been reported to date. But what we saw when we looked at overall survival was no statistical difference. The median was, and I know we do not like to talk about medians, but the median in the primary cytoreductive arm was 54 months versus 48 months in the neoadjuvant arm with a hazard ratio of 0.89 and, of course, the confidence interval crossed one. So this is not statistically significant. And that was the primary endpoint. Dr. Linda Duska: I know you are getting to this. They did look at PFS, and that was statistically significant, but to your point about what are we looking for for a reasonable PFS difference? It was about two months difference. When I think about this study, and I know you are coming to this, what I thought was most interesting about this trial, besides the fact that the OS, the primary endpoint was negative, was the subgroup analyses that they did. And, of course, these are hypothesis-generating only. But if you look at, for example, specifically only the stage III group, that group did seem to potentially, again, hypothesis generating, but they did seem to benefit from upfront surgery.  And then one other thing that I want to touch on before we run out of time is, do we think it matters if the patient is BRCA germline positive? Do we think it matters if there is something in particular about that patient from a biomarker standpoint that is different? I am hopeful that more data will be coming out of this study that will help inform this. Of course, unpowered, hypothesis-generating only, but it's just really interesting. What do you think of their subset analysis? Dr. Kathleen Moore: Yeah, I think the subsets are what we are going to be talking about, but we have to emphasize that this was a negative trial as designed. Dr. Linda Duska: Absolutely. Yes. Dr. Kathleen Moore: So we cannot be apologists and be like, "But this or that." It was a negative trial as designed. Now, I am a human and a clinician, and I want what is best for my patients. So I am going to, like, go down the path of subset analyses. So if you look at the stage III tumors that got complete cytoreduction, which was 70% of the cases, your PFS was almost 28 months versus 21.8 months. Dr. Linda Duska: Yes, it becomes more significant. Dr. Kathleen Moore: Yeah, that hazard ratio is 0.69. Again, it is a subset. So even though the P value here is statistically significant, it actually should not have a P value because it is an exploratory analysis. So we have to be very careful. But the hazard ratio is 0.69. So the hypothesis is in this setting, if you're stage III and you go for it and you get someone to no gross residual versus an interval cytoreduction, you could potentially have a 31% reduction in the rate of progression for that patient who got primary cytoreduction. And you see a similar trend in the stage III patients, if you look at overall survival, although the post-progression survival is so long, it's a little bit narrow of a margin.  But I do think there are some nuggets here that, one of our colleagues who is really one of the experts in surgical studies, Dr. Mario Leitao, posted this on X, and I think it really resonated after this because we were all saying, "But what about the subsets?" He is like, "It's a negative study." But at the end of the day, you are going to sit with your patient. The patient should be seen by a GYN oncologist or surgical oncologist with specialty in cytoreduction and a medical oncologist, you know, if that person does not give chemo, and the decision should be made about what to do for that individual patient in that setting. Dr. Linda Duska: Agreed. And along those lines, if you look carefully at their data, the patients who had an upfront cytoreduction had almost twice the risk of having a stoma than the patients who had an interval cytoreduction. And they also had a higher risk of needing to have a bowel resection. The numbers were small, but still, when you look at the surgical complications, as you've already said, they're higher in the upfront group than they are in the interval group. That needs to be taken into account as well when counseling a patient, right? When you have a patient in front of you who says to you, "Dr. Moore, you can take out whatever you want, but whatever you do, don't make me a bag." As long as the patient understands what that means and what they're asking us to do, I think that we need to think about that. Dr. Kathleen Moore: I think that is a great point. And I have definitely seen in our practice, patients who say, "I absolutely would not want an ostomy. It's a nonstarter for me." And we do make different decisions. And you have to just say, "That's the decision we've made," and you kind of move on, and you can't look back and say, "Well, I wish I would have, could have, should have done something else." That is what the patient wants. Ultimately, that patient, her family, autonomous beings, they need to be fully counseled, and you need to counsel that patient as to the site that you are in, her volume of disease, and what you think you can achieve. In my opinion, a patient with stage III cancer who you have the site and the capabilities to get to no gross residual should go to the OR first. That is what I believe. I do not anymore think that for stage IV. I think that this is pretty convincing to me that that is probably a harmful thing. However, I want you to react to this. I think I am going to be a little unpopular in saying this, but for me, one of the biggest take-homes from TRUST was that whether or not, and we can talk about the subsets and the stage III looked better, and I think it did, but both groups did really well. Like, really well. And these were patients with large volume disease. This was not cherry-picked small volume stage IIIs that you could have done an optimal just by doing a hysterectomy. You know, these were patients that needed radical surgery. And both did well. And so what it speaks to me is that anytime you are going to operate on someone with ovary, whether it be frontline, whether it be a primary or interval, you need a high-volume surgeon. That is what I think this means to me. Like, I would want high volume surgeon at a center that could do these surgeries, getting that patient, my family member, me, to no gross residual. That is important. And you and I are both in training centers. I think we ought to take a really strong look at, are we preparing people to do the surgeries that are necessary to get someone to no gross residual 70% and 85% of the time? Dr. Linda Duska: We are going to run out of time, but I want to address that and ask you a provocative question. So, I completely agree with what you said, that surgery is important. But I also think one of the reasons these patients in this study did so well is because all of the incredible new therapies that we have for patients. Because OS is not just about surgery. It is about surgery, but it is also about all of the amazing new therapies we have that you and others have helped us to get through clinical research. And so, how much of that do you think, like, for example, if you look at the PFS and OS rates from CHORUS and EORTC, I get it that they're, that they're not the same. It's different patients, different populations, can't do cross-trial comparisons. But the OS, as you said, in this study was 54 months and 48 months, which is, compared to 2010, we're doing much, much better. It is not just the surgery, it is also all the amazing treatment options we have for these patients, including PARP, including MIRV, including lots of other new therapies. How do you fit that into thinking about all of this? Dr. Kathleen Moore: I do think we are seeing, and we know this just from epidemiologic data that the prevalence of ovarian cancer in many of the countries where the study was done is increasing, despite a decrease in incidence. And why is that? Because people are living longer. Dr. Linda Duska: People are living longer, yeah. Dr. Kathleen Moore: Which is phenomenal. That is what we want. And we do have, I think, better supportive care now. PARP inhibitors in the frontline, which not many of these patients had. Now some of them, this is mainly in Europe, will have gotten them in the first maintenance setting, and I do think that impacts outcome. We do not have that data yet, you know, to kind of see what, I would be really interested to see. We do not do this well because in ovarian cancer, post-progression survival can be so long, we do not do well of tracking what people get when they come off a clinical trial to see how that could impact – you know, how many of them got another surgery? How many of them got a PARP? I think this group probably missed the ADC wave for the most part, because this, mirvetuximab is just very recently available in Europe. Dr. Linda Duska: Unless they were on trial. Dr. Kathleen Moore: Unless they were on trial. But I mean, I think we will have to see. 600 patients, I would bet a lot of them missed the ADC wave. So, I do not know that we can say we know what drove these phenomenal – these are some of the best curves we've seen outside of BRCA. And then coming back to your point about the BRCA population here, that is a really critical question that I do not know that we're ever going to answer. There have been hypotheses around a tumor that is driven by BRCA, if you surgically cytoreduced it, and then chemically cytoreduced it with chemo, and so you're starting PARP with nothing visible and likely still homogeneous clones. Is that the group we cured? And then if you give chemo first before surgery, it allows more rapid development of heterogeneity and more clonal evolution that those are patients who are less likely to be cured, even if they do get cytoreduced to nothing at interval with use of PARP inhibitor in the front line. That is a question that many have brought up as something we would like to understand better. Like, if you are BRCA, should you always just go for it or not? I do not know that we're ever going to really get to that. We are trying to look at some of the other studies and just see if you got neoadjuvant and you had BRCA, was anyone cured? I think that is a question on SOLO1 I would like to know the answer to, and I don't yet, that may help us get to that. But that's sort of something we do think about. You should have a fair number of them in TRUST. It wasn't a stratification factor, as I remember. Dr. Linda Duska: No, it wasn't. They stratified by center, age, and ECOG status Dr. Kathleen Moore: So you would hope with randomization that you would have an equal number in each arm. And they may be able to pull that out and do a very exploratory look. But I would be interested to see just completely hypothesis-generating what this looks like for the patients with BRCA, and I hope that they will present that. I know they're busy at work. They have translational work. They have a lot pending with TRUST. It's an incredibly rich resource that I think is going to teach us a lot, and I am excited to see what they do next. Dr. Linda Duska: So, outside of TRUST, we are out of time. I just want to give you a moment if there were any other messages that you want to share with our listeners before we wrap up. Dr. Kathleen Moore: It's an exciting time to be in GYN oncology. For so long, it was just chemo, and then the PARP inhibitors nudged us along quite a bit. We did move more patients, I believe, to the cure fraction. When we ultimately see OS, I think we'll be able to say that definitively, and that is exciting. But, you know, that is the minority of our patients. And while HRD positive benefits tremendously from PARP, I am not as sure we've moved as many to the cure fraction. Time will tell. But 50% of our patients have these tumors that are less HRD. They have a worse prognosis. I think we can say that and recur more quickly. And so the advent of these antibody-drug conjugates, and we could name 20 of them in development in GYN right now, targeting tumor-associated antigens because we're not really driven by mutations other than BRCA. We do not have a lot of things to come after. We're not lung cancer. We are not breast cancer. But we do have a lot of proteins on the surface of our cancers, and we are finally able to leverage that with some very active regimens. And we're in the early phases, I would say, of really understanding how best to use those, how best to position them, and which one to select for whom in a setting where there is going to be obvious overlap of the targets. So we're going to be really working this problem. It is a good problem. A lot of drugs that work pretty well. How do you individualize for a patient, the patient in front of you with three different markers? How do you optimize it? Where do you put them to really prolong survival? And then we finally have cell surface. We saw at ASCO, CDK2 come into play here for the first time, we've got a cell cycle inhibitor. We've been working on WEE1 and ATR for a long time. CDK2s may hit. Response rates were respectable in a resistant population that was cyclin E overexpressing. We've been working on that biomarker for a long time with a toxicity profile that was surprisingly clean, which I like to see for our patients. So that is a different platform. I think we have got bispecifics on the rise. So there is a pipeline of things behind the ADCs, which is important because we need more than one thing, that makes me feel like in the future, I am probably not going to be using doxil ever for platinum-resistant disease. So, I am going to be excited to retire some of those things. We will say, "Remember when we used to use doxil for platinum-resistant disease?" Dr. Linda Duska: I will be retired by then, but thanks for that thought. Dr. Kathleen Moore: I will remind you. Dr. Linda Duska: You are right. It is such an incredibly exciting time to be taking care of ovarian cancer patients with all the opportunities.  And I want to thank you for sharing your valuable insights with us on this podcast today and for your great work to advance care for patients with GYN cancers. Dr. Kathleen Moore: Likewise. Thanks for having me. Dr. Linda Duska: And thank you to our listeners for your time today. You will find links to the TRUST study and other studies discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Linda Duska  @Lduska Dr. Kathleen Moore Follow ASCO on social media:     @ASCO on X (formerly Twitter) ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures of Potential Conflicts of Interest:    Dr. Linda Duska:   Consulting or Advisory Role: Regeneron, Inovio Pharmaceuticals, Merck, Ellipses Pharma  Research Funding (Inst.): GlaxoSmithKline, Millenium, Bristol-Myers Squibb, Aeterna Zentaris, Novartis, Abbvie, Tesaro, Cerulean Pharma, Aduro Biotech, Advaxis, Ludwig Institute for Cancer Research, Leap Therapeutics  Patents, Royalties, Other Intellectual Property: UptToDate, Editor, British Journal of Ob/Gyn  Dr. Kathleen Moore: Leadership: GOG Partners, NRG Ovarian Committee Chair Honoraria: Astellas Medivation, Clearity Foundation, IDEOlogy Health, Medscape, Great Debates and Updates, OncLive/MJH Life Sciences, MD Outlook, Curio Science, Plexus, University of Florida, University of Arkansas for Medical Sciences, Congress Chanel, BIOPHARM, CEA/CCO, Physician Education Resource (PER), Research to Practice, Med Learning Group, Peerview, Peerview, PeerVoice, CME Outfitters, Virtual Incision Consulting/Advisory Role: Genentech/Roche, Immunogen, AstraZeneca, Merck, Eisai, Verastem/Pharmacyclics, AADi, Caris Life Sciences, Iovance Biotherapeutics, Janssen Oncology, Regeneron, zentalis, Daiichi Sankyo Europe GmbH, BioNTech SE, Immunocore, Seagen, Takeda Science Foundation, Zymeworks, Profound Bio, ADC Therapeutics, Third Arc, Loxo/Lilly, Bristol Myers Squibb Foundation, Tango Therapeutics, Abbvie, T Knife, F Hoffman La Roche, Tubulis GmbH, Clovis Oncology, Kivu, Genmab/Seagen, Kivu, Genmab/Seagen, Whitehawk, OnCusp Therapeutics, Natera, BeiGene, Karyopharm Therapeutics, Day One Biopharmaceuticals, Debiopharm Group, Foundation Medicine, Novocure Research Funding (Inst.): Mersana, GSK/Tesaro, Duality Biologics, Mersana, GSK/Tesaro, Duality Biologics, Merck, Regeneron, Verasatem, AstraZeneca, Immunogen, Daiichi Sankyo/Lilly, Immunocore, Torl Biotherapeutics, Allarity Therapeutics, IDEAYA Biosciences, Zymeworks, Schrodinger Other Relationship (Inst.): GOG Partners

Drs Joseph Mikhael and Sigurdur Y. Kristinsson discuss whether it is time to screen for multiple myeloma and what we can learn from the iStopMM study. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002717. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Multiple Myeloma https://emedicine.medscape.com/article/204369-overview Screening in Multiple Myeloma and Its Precursors: Are We There Yet? https://pubmed.ncbi.nlm.nih.gov/38175579/ Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM): A Population-Based Screening Study for Monoclonal Gammopathy of Undetermined Significance and Randomized Controlled Trial of Follow-Up Strategies https://pubmed.ncbi.nlm.nih.gov/34001889/ Identifying Associations Between Race and Gender in the Incidence and Mortality of Patients With Multiple Myeloma https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.e20052 Revisiting Wilson and Jungner in the Genomic Age: A Review of Screening Criteria Over the Past 40 Years https://pubmed.ncbi.nlm.nih.gov/18438522/ International Myeloma Foundation https://www.myeloma.org/ Prevalence of Monoclonal Gammopathy of Undetermined Significance https://pubmed.ncbi.nlm.nih.gov/16571879/ Monoclonal Gammopathy of Undetermined Significance https://www.ncbi.nlm.nih.gov/books/NBK507880/ Prevalence and Risk of Progression of Light-Chain Monoclonal Gammopathy of Undetermined Significance: A Retrospective Population-Based Cohort Study https://pubmed.ncbi.nlm.nih.gov/20472173/ Mode of Progression in Smoldering Multiple Myeloma: A Study of 406 Patients https://pubmed.ncbi.nlm.nih.gov/38228628/ Observation or Treatment for Smoldering Multiple Myeloma? A Systematic Review and Meta-Analysis of Randomized Controlled Studies https://pubmed.ncbi.nlm.nih.gov/40419473/

This inspiring episode focuses on women leading innovation in medicine, as Dr. Hilary Longhurst and Mrinal Shah break down the revolutionary intersection of patient advocacy, clinical courage, and gene-editing technology for rare diseases like Hereditary Angioedema (HAE). Dr. Longhurst shares the moment she felt her voice and vision were challenged as a woman and the critical lesson that her greatest failures were "sins of omission," inspiring her to be brave and always represent the patient. Mrinal Shah discusses the importance of protecting curiosity and creativity in large systems, offering powerful advice to the next generation of women scientists: embrace change and have faith in yourself. The conversation highlights the essential role of women leaders in stepping outside conventional guidelines, forging courageous collaborations, and driving the responsible innovation that makes the impossible happen for patients globally. This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities.

This episode features two nurse practitioners, Laura Demuth and Jackie Gianelli, who are not just managing careers but actively carving out new, non-traditional roles that place women's whole-person health at the center of care. Both leaders reflect on the systemic barriers that have slowed progress in women's health—from underfunded research in areas like menopause and endometriosis to flawed reimbursement models—and reveal how their clinical skills, like critical thinking and cross-functional leadership, made the leap to executive roles possible. Ultimately, they offer a collective mantra to clinicians feeling "boxed in": follow your curiosity, know you have options, and don't take the first "no" as gospel. This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities.

Drs Joseph Mikhael and Peter Voorhees discuss considerations for treating smoldering multiple myeloma, including recent studies and shared decision-making. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002716. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Observation or Treatment for Smoldering Multiple Myeloma? A Systematic Review and Meta-Analysis of Randomized Controlled Studies https://pubmed.ncbi.nlm.nih.gov/40419473/ Monoclonal Gammopathy of Undetermined Significance https://www.ncbi.nlm.nih.gov/books/NBK507880/ From Criteria to Clinic: How Updated Slim CRAB Criteria Influence Multiple Myeloma Diagnostic Activity https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.7556 International Myeloma Working Group Risk Stratification Model for Smoldering Multiple Myeloma (SMM) https://pubmed.ncbi.nlm.nih.gov/33067414/ Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/39652675/ Lenalidomide-Dexamethasone Versus Observation in High-Risk Smoldering Myeloma After 12 Years of Median Follow-Up Time: A Randomized, Open-Label Study https://pubmed.ncbi.nlm.nih.gov/36067617/ Long-Term Outcome With Lenalidomide and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/23648667/ CD38-Directed Therapies for Management of Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/34235096/ Fixed Duration Therapy With Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma – Results of the Ascent Trial https://ashpublications.org/blood/article/140/Supplement%201/1830/492739/Fixed-Duration-Therapy-with-Daratumumab Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (Krd) Followed by Transplant, Krd Consolidation, and Rd Maintenance https://pubmed.ncbi.nlm.nih.gov/39038268/ Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucel in High-Risk Smoldering Myeloma https://ashpublications.org/blood/article/144/Supplement%201/1027/531466/Early-Safety-and-Efficacy-of-CAR-T-Cell-Therapy-in

Why is menopause care still fragmented? Dr. Alyssa Dweck, Dr. Mary Jane Minkin, and Heather Maurer dig into the “menopause desert,” the WHI legacy, workplace fixes, and how NPs and clinicians can personalize evidence-based care—without the stigma or misinformation. This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities. Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002974?ecd=bdc_podcast_libsyn_mscpedu

Welcome to The Mental Breakdown and Psychreg Podcast! Today, Dr. Berney and Dr. Marshall discuss the misinformation in the media about the relationship between Autism, Tylenol, and vaccinations. Read the article from Medscape here. You can now follow Dr. Marshall on twitter, as well! Dr. Berney and Dr. Marshall are happy to announce the release of their new parenting e-book, Handbook for Raising an Emotionally Healthy Child Part 2: Attention. You can get your copy from Amazon here. We hope that you will join us each morning so that we can help you make your day the best it can be! See you tomorrow. Become a patron and support our work at http://www.Patreon.com/thementalbreakdown. Visit Psychreg for blog posts covering a variety of topics within the fields of mental health and psychology. The Parenting Your ADHD Child course is now on YouTube! Check it out at the Paedeia YouTube Channel. The Handbook for Raising an Emotionally Health Child Part 1: Behavior Management is now available on kindle! Get your copy today! The Elimination Diet Manual is now available on kindle and nook! Get your copy today! Follow us on Twitter and Facebook and subscribe to our YouTube Channels, Paedeia and The Mental Breakdown. Please leave us a review on iTunes so that others might find our podcast and join in on the conversation!

This episode features a powerful discussion with Dr. Padma Mahant, Director of Medical Affairs, CND Life Sciences, and Dr. Indu Subramanian, a Neurologist with UCLA, who are leading the charge to correct the biases in Parkinson's disease care. They expose a critical gap where women's unique, non-motor symptoms are often overlooked, resulting in twice as many women waiting five or more years for a proper diagnosis compared to men. The conversation highlights the imperative to move beyond the "cookie-cutter" approach by leveraging new, objective diagnostic tools to aid early detection, prioritizing women's inclusion in clinical research, and adopting a compassionate, integrative model that places the patient at the center of their own wellness journey. This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities. https://www.medscape.org/viewarticle/1002954

EP. 232:  Grab my FREE 4 Part Video Series: GLP1s Uncovered: https://bit.ly/GLP1uncovered In this episode I'm clearing up the confusion and political noise around Tylenol and NSAIDs. These over the counter medications are handed out like candy, yet decades in practice treating pain have shown me how often they backfire: from gut damage and hormone disruption to stalled healing and liver stress. Add in the recent headlines about Tylenol's potential link to autism, and suddenly what was once considered safe has become a lightning rod of controversy. I'll break it down simply: what these meds really do in the body, why long-term reliance can set you up for bigger problems, and how to think critically instead of getting caught in the political crossfire. This is not about fear. It is about facts, context, and giving you tools to make better choices for your health. Plus I let you know what to you can do instead. Topics Discussed:→ Is Tylenol safe for long-term use?→ What are the risks of ibuprofen and other NSAIDs?→ How does Tylenol affect liver and gut health?→ What are safer alternatives for pain relief?→ Why was the Vioxx scandal important for pain management? Sponsored By: → Qualia | Go to qualialife.com/drtyna for up to 50% off at and use code DRTYNA for an extra 15% off.  → Sundays | Go to sundaysfordogs.com/DRTYNA and use code DRTYNA at checkout. → Graza | So head to Graza.co/DRTYNA and use DRTYNA to get 10% off and get to cookin' your next chef quality meal! → Manukora | Head to manukora.com/DRTYNA to save up to 31% & $25 worth of free gifts in the Starter Kit, which comes with an MGO 850+ Manuka Honey jar. On This Episode We Cover:  → 00:00:00 - Introduction → 00:04:44 - Medscape findings and Tylenol → 00:08:16 - Tylenol and neurodevelopment concerns → 00:13:51 - Common sources of acetaminophen → 00:16:31 - Risks of NSAIDs → 00:19:15 - A brief history of pain relief → 00:23:05 - The Vioxx scandal explained → 00:29:12 - Safe NSAID dosing → 00:33:15 - Tylenol PM and its issues → 00:34:12 - Black box warnings → 00:36:54 - Bone health risks and more → 00:39:16 - Gut and pregnancy safety → 00:42:46 - COX pathways and cartilage effects → 00:45:25 - Approaches to pain management → 00:50:02 - Hormones, HRT, and pain relief → 00:53:41 - Liver health considerations → 00:57:04 - Peptides and microdosing → 01:03:26 - Reliable herbal options Show Links:  → Acetaminophen Use During Pregnancy, Behavioral Problems, And Hyperkinetic Disorders → Evaluation Of The Evidence On Acetaminophen Use And Neurodevelopmental Disorders Using The Navigation Guide Methodology Further Listening:  → EP: 227 | How I Broke Free From The Pain Trap | Solo → EP. 221 | The GLP-1 Microdosing Lie: It's NOT a Weight Loss Strategy | Solo → EP. 196 | The Answer Is The Gym | Quick + Dirty → EP. 82: Movement Overrides Pain - Solo Episode → EP. 22: Solo Episode: The Not So Easy Answer to Pain Management → Playlists (Orthopedics, Hormones, Strength Training + More) Disclaimer: Information provided in this podcast is for informational purposes only. This information is NOT intended as a substitute for the advice provided by your physician or other healthcare professional, or any information contained on or in any product. Do not use the information provided in this podcast for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before taking any medication or nutritional, herbal or other supplement, or using any treatment for a health problem. Information provided in this blog/podcast and the use of any products or services related to this podcast by you does not create a doctor-patient relationship between you and Dr. Tyna Moore. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent ANY disease.

Joseph Mikhael, MD, and Krina K. Patel, MD, MSc, discuss considerations for CAR T-Cell therapy in multiple myeloma, including age, access, and bridging therapy. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002715. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Multiple Myeloma https://emedicine.medscape.com/article/204369-overview CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.8009 Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/37272512/ Plain Language Summary of the KarMMa-3 Study of Ide-cel or Standard of Care Regimens in People With Relapsed or Refractory Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/38651976/ CAR T-Cell Therapy Toxicity https://www.ncbi.nlm.nih.gov/books/NBK592426/ Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience https://pubmed.ncbi.nlm.nih.gov/28205024/ Incidence and Outcomes of Cytomegalovirus Reactivation After Chimeric Antigen Receptor T-Cell Therapy https://pubmed.ncbi.nlm.nih.gov/38838226/ Long-Acting Granulocyte Colony-Stimulating Factor in Primary Prophylaxis of Early Infection in Patients With Newly Diagnosed Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/35064823/ Revisiting the Role of Alkylating Agents in Multiple Myeloma: Up-to-Date Evidence and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/37244325/ Bispecific Antibodies for the Treatment of Relapsed/Refractory Multiple Myeloma: Updates and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/38660139/ FDA Eliminates REMS for Approved CAR T-Cell Therapies https://www.aabb.org/news-resources/news/article/2025/06/30/fda-eliminates-rems-for-approved-car-t-cell-therapies

About this Episode Episode 49 of “The 2 View” – New IDSA Complicated UTI Guidelines, Pediatric Nicotine OD, Hepatitis C Screening in the ED, High-Risk Delta Troponins Segment 1A – Pediatric Nicotine Ingestion Madelyn O, Hays HL, Kistamgari S, et al. Nicotine Ingestions Among Young Children: 2010–2023. Pediatrics. 2025;156(2):e2024070522. doi:10.1542/peds.2024-070522. Segment 1B – Finger Thoracostomy and Traumatic Pneumothorax/Hemothorax Blank, J, de Moya MA. Traumatic pneumothorax and hemothorax: What you need to know. J Trauma Acute Care Surg. Published online July 3, 2025. doi:10.1097/TA.0000000000004692 Beyer CA, Ruf AC, Alshawi AB, Cannon JW. Management of traumatic pneumothorax and hemothorax. Curr Probl Surg. 2025;63. doi:10.1016/j.cpsurg.2024.101707. Weingart, S. EMCrit 62 – Needle vs. Knife II: Needle Thoracostomy (Decompression)? EMCrit. Published online December 11, 2011. https://emcrit.org/emcrit/needle-finger-thoracostomy/ Lange C, Sharma M. Podcast #223 - ATLS Episode 4: Thoracic Trauma (Chapter 4). Total EM. October 27, 2020. https://www.totalem.org/emergency-professionals/podcast-223-atls-episode-4-thoracic-trauma-chapter-4 Segment 2A – Hepatitis C Screening in EDs Haukoos J, Rothman RE, Galbraith JW, et al. Hepatitis C Screening in Emergency Departments: The DETECT Hep C Randomized Clinical Trial. JAMA. 2025;334(6):497–507. doi:10.1001/jama.2025.10563 Segment 2B – Serial HS-Troponin Patterns Huggins C, Saltarell Ni, Swoboda TK, et al. Kinetic changes in high-sensitivity cardiac troponin for risk stratification of emergency department chest pain patients. Am J Emerg Med. 2025;93:176-181. doi:10.1016/j.ajem.2025.04.010. Segment 3 - Updated IDSA Guidelines on Complicated Urinary Tract Infections Splete H. IDSA Updates Guidelines on Complicated UTIS. Medscape. Published online July 18, 2025. https://www.medscape.com/viewarticle/idsa-updates-guidelines-complicated-utis-2025a1000j3l Trautner BW, Cortes-Penfield NW, Gupta K, et al. Complicated Urinary Tract Infections (cUTI): Clinical Guidelines for Treatment and Management. IDSA. Published online July 17, 2025. https://www.idsociety.org/practice-guideline/complicated-urinary-tract-infections/ Roberts M, Sharma M. 34 - Pertussis, Computer Interpretation of EKGs, Tuberculosis, Fluoroquinolone Side Effects. The 2 View. Published online April 10, 2024. https://2view.fireside.fm/34 Roberts M, Sharma M. 46 - Heat Stroke Tx, A New Virus, Oral Cephalosporins Vs Pyelo, Safe Discharges. The 2 View. Published online June 11, 2025. https://2view.fireside.fm/46 Bonus Reference – Ponytail Headache Blau JN. Ponytail Headache: A Pure Extracranial Headache. Headache. 2004;44(5):411-413. doi: 10.1111/j.1526-4610.2004.04092.x. Recurring Sources Center for Medical Education. http://ccme.org The Proceduralist. http://www.theproceduralist.org The Procedural Pause. https://journals.lww.com/em-news/blog/theproceduralpause/pages/default.aspx The Skeptics Guide to Emergency Medicine. http://www.thesgem.com Be sure to keep tuning in for more great prizes and fun trivia questions! Once you hear the question, please email us your guesses at 2viewcast@gmail.com and tell us who you want to give a shout-out to.

Survey Side Hustle Showdown: Real Reviews of Sermo, ZoomRx & MoreEver wondered if those emails about “quick clinical surveys for cash” are legit? In this episode of The PA Is In, I'm diving deep into the top survey platforms for medical professionals—breaking down the pros, cons, and real earning potential of sites like Sermo, ZoomRx, MD4Lives, InCrowd, and more.This episode is your complete guide to turning survey invites into a little side income—and deciding which platforms are worth your time (and which ones to avoid).What You'll Learn:My real earnings from survey platforms like Sermo & ZoomRxWhich sites pay in cash vs. points (and what that really means)Why Sermo is more than just surveys—hello, community!Transparency around MD4Lives paymentIf Medscape ever sends actual surveysHow to stack small streams of income while you scrollLinks: SERMO: https://app.sermo.com:443/?sermoref=39d97a2c-f699-4f8b-b2f9-1eb131e18c75&utm_campaign=tell-a-friendZOOMRX: https://refer.zoomrx.com/tracyb2 Keywords: medical surveys for clinicians, side hustle for PAs, survey income for doctors, Sermo survey review, ZoomRx for healthcare providers, MD4Lives payment delay, Medscape survey payout, InCrowd review, OpinionSite survey cashout, best medical survey sites 2025, clinician side income ideas, non-clinical income for NPs, paid medical surveys, survey platforms for physician associates, how to make money answering surveys

The Skin Real app is officially LIVE! Download it now. Download my Free Guide 'In My Perimenopause Era' Download the Ultimate Affordable Skincare Guide When was the last time you thought about your vulvar health? If your answer is “never,” you're not alone. Most women avoid talking or even thinking about this part of their body, but during perimenopause and menopause, changes in vulvar and vaginal health can have a huge impact on your comfort, confidence, and quality of life. In this episode, I sit down with Dr. Diana Londoño, a urologist who is breaking the silence on intimate health. We talk about the changes estrogen loss brings—from dryness, itching, painful sex, and recurrent UTIs to the lesser-known issues like bladder urgency and vulvar atrophy. She also explains how simple solutions like vaginal estrogen cream, hormone therapy, and lifestyle tweaks can protect your vulvar health and prevent years of suffering. ✨ Key Takeaways: Why vulvar health is central to your bladder, vaginal, and sexual health during menopause. How to know if your symptoms are normal aging or a red flag that needs further evaluation. The connection between UTIs, GSM (genitourinary syndrome of menopause), and vulvar atrophy. Why vaginal estrogen is safe, preventative, and worth considering even if you're not sexually active. How stress and mindset affect bladder symptoms and overall well-being. If you've ever felt embarrassed, ignored, or confused about what's happening “down there,” this episode will give you clarity and confidence. Dr. Diana Londoño is a Board-Certified Urologist and one of the 10% of urologists in the US who are women and the 0.5% who are Latinx and women.  She is originally from Mexico City and attended Claremont McKenna College for her undergraduate studies and then went on to attend UCLA for medical school.  She completed a 6-year residency in Urology at Kaiser Permanente in Los Angeles.   She has experienced burnout twice, which has led her to write and speak about it to raise awareness and help others. She has published multiple articles in prominent medical platforms, including Medscape, Doximity, Kevin MD, Men's Health, Giddy.com, and WebMD, among others. She is also a contributing author to the books “Thriving After Burnout” and “Medic S.O.S.”  She has also been a guest on numerous podcasts, discussing various topics, including wellness, stress, spirituality, and energy.   Her burnout journey led her to become a certified life coach and founder of Physician Coach Support.com, a peer support platform she ran for 3 years. In 2022, she received the Los Angeles County Medical Association Physician Leadership Award for her work.    She is an international speaker and guest on multiple podcasts, discussing topics such as wellness, boundaries, ego, humanity in medicine, mindset, and mindfulness. She has also been featured on TV on Univision, Telemundo, Mundo Fox, CNN Latino, KCET, and ABC News as a health consultant discussing urological topics.   She is also a Reiki Master, a Pranic Healer and the mother of two determined and joyful 7- —and 9-year-old girls, Daniela and Paloma.   Follow Dr. Londoño here:   Website -https://dianalondonomd.com/ LinkedIn - https://www.linkedin.com/in/dianalondonomd/ Instagram - https://www.instagram.com/dianalondonomd/ YouTube - https://www.youtube.com/@dianalondonomd   Want more expert skin advice without the overwhelm? Subscribe to The Skin Real Podcast wherever you listen, and visit www.theskinreal.com for dermatologist-backed tips to help you feel confident in your skin—at every age. Follow Dr. Mina here:-  https://instagram.com/drminaskin https://www.facebook.com/drminaskin https://www.youtube.com/@drminaskin https://www.linkedin.com/in/drminaskin/ Visit Dr. Mina at Baucom & Mina Derm Surgery Website: atlantadermsurgery.com Email: scheduling@atlantadermsurgery.com Call: (404) 844-0496 Instagram: @baucomminamd Thanks for tuning in. And remember—real skin care is real simple when you know who to trust. Disclaimer: This podcast is for entertainment, educational, and informational purposes only and does not constitute medical advice.      

Did you know that the happiest doctors in 2025 don't work in hospitals—and they're not who you think?If you're a physician feeling overwhelmed by call schedules, burnout, or lack of work-life balance, this episode unpacks real data on the medical specialties where doctors are thriving—not just surviving.Discover the top 5 happiest medical specialties based on a 2025 Medscape survey.Learn the common traits these specialties share (hint: they involve zero emergency calls).Find out what this means for your own career shift from corporate to independent practice.Hit play now to uncover which specialties top the physician happiness list and share this episode with a colleague.Source: https://www.inspiraadvantage.com/blog/the-happiest-medical-specialtiesTEXT HERE to suggest a future episode topic Discover how medical graduates, junior doctors, and young physicians can navigate residency training programs, surgical residency, and locum tenens to increase income, enjoy independent practice, decrease stress, achieve financial freedom, and retire early, while maintaining patient satisfaction and exploring physician side gigs to tackle medical school loans.

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Kara Pepper, MD, for joining me on this episode of The Art of Medicine with Dr. Andrew Wilner! Dr. Pepper is an internal medicine physician and former professional ballet dancer. After her residency in internal medicine, Dr. Pepper joined a corporate medical practice. Although she felt it wasn't the perfect fit, she stuck with it. After about seven years, she succumbed to burnout and left on sabbatical. She resumed her job but still wasn't satisfied. The stark reality of the COVID pandemic forced Kara to reassess her priorities. Three years ago, she left corporate medicine to create a solo practice. What began as a telemedicine practice now includes in-person visits as well. She specializes in treating patients with eating disorders. By running her own practice, Dr. Pepper feels she can better serve patients, especially those who feel marginalized by the health care system. Dr. Pepper also discovered a community of physicians who struck out on their own and developed satisfying and successful practices. She happily shares her experience as a physician coach with other doctors who are unhappy in medicine and considering solo practice. She emphasized that "physicians have a voice and autonomy…are not prisoners of their jobs, and can create something new." To learn more about creating a successful solo practice, check out her website: www.karapeppermd.com or contact Kara Pepper, MD: hello@karapeppermd.com  #AI #ambientscribe #locumtenens #solopractice #eatingdisorders #womenentrepreneurPlease click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: https://locumstory.com/?source=DSP_directbuy_drwilnerpodcast_ph...

Send us a textWhy are U.S. health care costs so high—and what does that mean for you and your family? In this episode, I dive into the real reasons behind America's staggering health care bills.We start with a story that hits close to home—a $189,000 outpatient cancer surgery bill followed by $12,000-a-month immunotherapy—and I unpack how even with Medicare coverage, the pricing dynamics can feel shocking. Using my experience as a physician and health policy researcher, I explain why these massive charges happen and where the system is breaking down.At the national level, we now spend over $5 trillion a year on health care—roughly 18% of our GDP—and this number is growing far faster than inflation. This growth threatens the solvency of key programs like Medicare, which is projected to run out of funds by 2033 (Health Affairs). Employers are also feeling the pinch, with average family coverage costs now topping $25,500 annually (WSJ). Individuals, especially those using ACA exchanges, face rising premiums—some increasing by 20–30% next year (Axios)—and deductibles between $3,000 and $5,000 are now typical.Despite all this spending, our health outcomes are among the worst in the developed world. The U.S. ranks 33rd in infant mortality and 32nd in life expectancy out of 38 OECD countries, even though we spend about $12,000 per person annually—nearly three times the OECD average (America's Health Rankings).So, what drives these costs? It boils down to three factors: high prices, high utilization, and high administrative overhead. Prices for common procedures are far above international norms—a CT scan in the U.S. costs around $900 compared to $279 in the Netherlands and just $97 in Canada (Health Imaging). U.S. physicians, nurses, and hospital executives also earn significantly more, contributing to overall spending (Medscape; JAMA).On the utilization front, studies estimate that around 25% of all care may be unnecessary, driven by defensive medicine, patient expectations, and incentive structures that reward more procedures—not necessarily better outcomes (PGPF; Choosing Wisely).Even administrative overhead plays a massive role: nearly 25% of U.S. health care spending goes to bureaucracy—four times what's typical in simpler, single-payer systems (Health System Tracker; Health Affairs%20of%20US%20GDP)).If you're wondering why your doctor spends just 17 minutes with you or why your premiums feel like a second mortgage, this episode offers the context—and data—to help you understand what's really going on.Takeaways: Start asking about cash prices—especially if you're still in your deductible phase. Preventive steps like regular exercise may offer the highest return on investment when compared to costly downstream care. And above all, consider your plan carefully during open enrollment.For deeper insights, links to all the studies mentioned, and access to my newslet

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Rashie Jain for joining me on this episode of The Art of Medicine with Dr. Andrew Wilner!  Rashie is an engineer and Co-Founder of Marvix.AI, her second start-up. Rashie observed that many physicians struggle with high administrative burdens, especially medical specialists who spend more time with patients and deal with complex cases. With the advent of large language models, she created an "ambient scribe" that takes notes during a patient encounter, organizes them, and presents them for review as a finished product. With just a little tweaking, doctors can embed these notes into the electronic medical record (EMR). I tried out Rashie's software at the recent American Academy of Neurology meeting in San Diego, CA. Her Co-Founder played the role of a migraine patient, and we chatted for about 10 minutes. Truth be told, the ambient scribe did a great job capturing the essential details. I could have edited it in just a couple of minutes, which would save time compared to typing it into the EMR myself! To learn more about Marvix.AI, or to try it in your own office, please contact Rashie Jain at https://www.marvixapp.ai#AI #ambientscribe #largelanguagemodel #womenentrepreneurPlease click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: https://locumstory.com/?source=DSP_directbuy_drwilnerpodcast_ph...

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Brenda Snow for joining me on this episode of The Art of Medicine with Dr. Andrew Wilner!  Brenda is the Founder and CEO of Snow Companies, which helps engage patients with their healthcare services. Her own life-changing experience with a neurologic disorder, which she experienced as an "identity earthquake," triggered the creation of her business, "Snow Companies." Thirty years ago, Brenda suffered from unexplained symptoms including double vision, dragging her left foot, loss of bladder control, and strange fatigue. After initial misadventures with a couple of neurologists, she was accurately diagnosed with multiple sclerosis. Brenda eventually discovered a supportive medical team. She takes regular multiple sclerosis treatments, maintains a healthy lifestyle, and lives an active and successful life. Brenda started "Snow Companies" nearly 25 years ago. Now with over 400 employees, Snow Companies helps pharmaceutical companies engage with their patients. Brenda also hopes to help patients with her new book, "Diagnosed: The Essential Guide to Navigating the Patient's Journey." Brenda graciously offered to send a free, signed copy of her book to anyone who can't afford it. Just send her an email through her website: https://brendasnow.com #multiple sclerosis #womenentrepreneurs #entrepreneurs #authorPlease click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: https://locumstory.com/?source=DSP_directbuy_drwilnerpodcast_ph...

Join medical students Binal Patel and Aashka Sheth as they discuss adolescent gynecology with pediatrician Dr. Shreeti Kapoor.  Specifically, they will discuss: What exactly is adolescent gynecology. The proper approach to taking a comprehensive history for a pediatric patient with a gynecologic chief complaint. The various causes of dysmenorrhea in the early menarche period and its presentation. The diagnostic approach to dysmenorrhea in adolescents. The approach to treatment of dysmenorrhea in a pediatric population. And how to approach addressing safe sex practices and sexually transmitted infections with adolescents. References: 21 reasons to see a gynecologist before you turn 21. ACOG. (n.d.). https://www.acog.org/womens-health/infographics/21-reasons-to-see-a-gynecologist-before-you-turn-21   Adams Hillard P. J. (2008). Menstruation in adolescents: what's normal?. Medscape journal of medicine, 10(12), 295.  Breehl L, Caban O. Physiology, Puberty. [Updated 2023 Mar 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534827/  Centers for Disease Control and Prevention. (n.d.). About heavy menstrual bleeding. Centers for Disease Control and Prevention. https://www.cdc.gov/female-blood-disorders/about/heavy-menstrual-bleeding.html  Primary dysmenorrhea in adolescents. UpToDate. (n.d.). https://www.uptodate.com/contents/primary-dysmenorrhea-in-adolescents?search=Primary+Dysmenorrhea+&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2  professional, C. C. medical. (2024, September 20). Pediatric gynecology. Cleveland Clinic. https://my.clevelandclinic.org/health/articles/24574-pediatric-gynecology  professional, C. C. medical. (2025, February 18). Puberty. Cleveland Clinic. https://my.clevelandclinic.org/health/body/puberty   Sachedin, A., & Todd, N. (2020). Dysmenorrhea, endometriosis and chronic pelvic pain in adolescents. Journal of Clinical Research in Pediatric Endocrinology, 12(1), 7–17. https://doi.org/10.4274/jcrpe.galenos.2019.2019.s0217   Sexuality, Sexual Health, and Sexually Transmitted Infections in Adolescents and Young Adults. (2020). Topics in Antiviral Medicine, 28(2). https://pmc.ncbi.nlm.nih.gov/articles/PMC7482983/pdf/tam-28-459.pdf   UpToDate. (n.d.). Abnormal uterine bleeding in adolescents. https://www.uptodate.com/contents/abnormal-uterine-bleeding-in-adolescents-evaluation-and-approach-to-diagnosis?search=heavy%2Bbleeding&usage_type=default&source=search_result&selectedTitle=3~150&display_rank=3  

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Matt Holgotz-Hetling for joining me on this episode of The Art of Medicine with Dr. Andrew Wilner! Matt is a journalist and author of "If it Sounds Like a Quack…" His prior book, "A Libertarian Walks into a Bear," received 4.5 stars on Amazon and more than 1,000 reviews. During COVID, Matt took an interest in two conflicting forces he observed in American society. On the one hand, public health officials were trying to protect the public by recommending masks and closing schools. On the other hand, many independent-minded Americans insisted on making their own decisions, often eschewing masks and social distancing.  Matt was intrigued by fringe practitioners offering cures for COVID, which included baking soda, bleach, lasers, and leeches. Many alternative medicine practitioners had faith in their "One True Cure." Of course, it was difficult to eliminate greed and exploitation as supporting motivations. Matt and I had an in-depth conversation for nearly an hour! It was a treat to speak with such an informed and thoughtful author. Matt's newest book, "The Ghost Lab," should be available shortly. You can find all of Matt's books on Amazon. To learn more, please check out Matt's website:https://www.matt-hongoltzhetling.com#concussion #CTE #traumatic brain injury #TBI Please click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: https://locumstory.com/?source=DSP_directbuy_drwilnerpodcast_ph...

This is Sara, and I remember the time 20 years ago when I got schooled by a psychoanalyst.  It must have been the fall, because I was supremely agitated that I was having to write, design, and send holiday cards out to a huge list of people all by myself, without the help of my fiancé.  If you know me, you know that cards were a staple of my winter growing up, with cards from my parents' friends stapled onto long felt ribbons hanging down each doorway, surrounding us with love and smiling faces for weeks on end.  The therapist asked if I could just not do them, if it was annoying me so much, and my instant fury was revealed: Are you kidding? I have to send these cards out, it's the nice thing to do!!  Cut to the point, and it's this - nice according to who?  Nice for whom?  Certainly not nice for me if I were going to be resentful and pissy about it.  I came to terms with the fact that I actually just really enjoyed writing and sending cards out to people who warmed my heart that year, and that my partner wasn't a nice person for not agreeing to send these cards out with me.   But it leads us to ask this.  What do we mean by niceness - and what, more importantly, is its not-as-related-as-it-seems and so much more important character trait of kindness?  How can understanding this difference and leaning into kindness help us be better people?   What to listen for: How a medically trained doctor got into a “touchy-feely” thing like kindness The shockingly tremendous impact that kindness has on our individual health and our societal wellbeing What's the difference between niceness vs kindness?  Ways to begin practicing more kindness About our guest:   Kelli Harding, MD, MPH, is dedicated to creating a kinder and healthier world for all. An expert in mental health, medicine, and public health, she teaches at Columbia University's Vagelos College of Physicians and Surgeons (VP&S) in New York City and is a diplomate of the American Board of Psychiatry and Neurology, also boarded in the sub-specialty of consultation-liaison psychiatry or psychosomatic (mind-body) medicine. Known for making complex scientific research understandable to general audiences, she's the author of the critically acclaimed book The Rabbit Effect: Live Longer, Happier, and Healthier with the Groundbreaking Science of Kindness. Dr. Harding has appeared on Today, Good Morning America, BBC, The New York Times, The Washington Post, Prevention, LA Times, Oprah Magazine, Parents, Medscape, Sesame Street Workshop, and The World Economic Forum. Additionally, she has spoken at global events at the United Nations and World Happiness Summits and served on the Boards of Organizations such as the Association of American Medical Colleges (AAMC) and social media platform Nextdoor. Dr. Harding lives in New York City with her husband and three sons—an eleventh-grader, a ninth-grader, and a sixth-grader, and beloved rescue pup, Athena. Her next book, Different, co-authored with Sara Blanchard, will be out in Fall 2026. Website kellihardingmd.com LinkedIn Kelli Harding MD MPH Instagram @kellihardingmd

Navigating Medicine and Faith: A Conversation with Dr. Sharon Stoll In this episode, Dr. Sharon Stoll discusses her background growing up in a modern Orthodox Jewish community in Philadelphia, her journey to becoming a neuroimmunologist, and her professional experiences working at Yale and now in Philadelphia. The conversation touches on her approach to patient education, especially around COVID-19 and various medications, including GLP-1 agonists like Ozempic and SSRIs for mental health. Dr. Stoll also speaks about her role in JOWMA (Jewish Orthodox Women's Medical Association) and the importance of educating her community on medical issues.    The discussion covers her views on IVF, the ethical considerations of genetic selection, and the interplay of anxiety and genetic predispositions within the Ashkenazi Jewish community. Dr. Stoll shares personal anecdotes and insights into balancing professional and personal life, making this an in-depth and enlightening conversation.   00:00 Introduction and Background 01:19 Professional Journey and Achievements  02:08 Balancing Media and Medicine 03:48 Involvement with Jowma 05:40 Views on Vaccination 14:26 Discussion on SSRIs and Ozempic 28:16 Challenges in the Frum Community  34:38 Debunking Misconceptions About Diabetes 35:07 Educational Gaps and Community Efforts 36:43 Health Education in Schools 39:06 Challenges of Motherhood and Societal Expectations 43:43 Genetic Risks and Mental Health in Ashkenazi Jews 54:38 IVF, Genetic Selection, and Ethical Dilemmas  01:02:34 Concluding Thoughts and Personal Reflections   About Our Guest: Dr. Sharon Stoll is a board-certified neurologist, neuro-immunologist. She currently serves as Director of Neurology at Stoll Medical Group in Philadelphia. For the past 8 years she worked as assistant professor, in the department of neurology at Yale School of Medicine. She completed her neurology residency training at Thomas Jefferson University Hospital in Philadelphia and her Neuroimmunology fellowship at Yale New Haven Hospital. Dr. Stoll played an active role in academic development and continuing medical education. She currently serves on several steering committees and advisory boards. She has been published in numerous peer-reviewed journals and served as Principal Investigator on several clinical trials. Dr. Stoll has received numerous awards, including Top Neurologist, 40 under 40, the Rodney Bell teaching award, and is a national multiple sclerosis society grant recipient. Dr. Stoll is also a medical editor for Medscape and Healthline and previously worked as a medical editor for ABC News. She is also a medical commentator for several national and local news outlets, including ABC, NBC, and CBS News, and has been on a variety of shows, including “The Doctors”. She is an internationally renowned speaker and patient advocate.   https://www.drsharonstoll.com https://www.instagram.com/drsharonstoll/?hl=en https://www.jowma.org  

Podcast: LAS NOTICIAS CON CALLE DE 14 DE MARZO DE 2025 - Alerta rosa por joven de 24 años desaparecida en Yabucoa - Maestra de Biblia y caso sexual con “menores” puede tener otro ángulo importante - El Nuevo Día - Queman carro con cuerpo dentro en Vega Alta- Accidente cierra autopista de San Juan a Manatí - Putin pide un riñón y un pulmón para la paz con Ucrania - FT- Se entregan demócratas en pelea por presupuesto federal - Punchbowl News - El oro llega a 3 mil billetes - Bloomberg - China hacía trampa y ahora se preocupa por aranceles indirectos - NYT- El costo no hacer algo sobre el cambio climático es mayor que el hacerlo - Metro - Gobe respalda construcción de Rincón que causó protesta tras situación con camiones - El Nuevo Día- Guillito estaba más al garete que Mireddys dirigiendo empresas según DY - El Vocero - Muere Raúl Grijalva de cáncer - Primera Hora- A la venta hotel de Maricao - El Nuevo Día- Otra vez dicen que ahora sí viene reforma de permisos y que esta vez funcionará - El Nuevo Día- Vienen aumento a multas a empresas de energía por incumplimientos con negociado - El Vocero- Jgo pide buscar viviendas sin titularidad bajo el gobierno para pasarle a personas - El Nuevo Día- Gobe va a decidir ciertos ascensos en la policía contrario a DSP - El Nuevo Día- MedScape publica historia de posible relación de la comida y la baja en fertilidad - Gobierno de PR celebra que quiten leyes ambientales federales para moverse a energía fósil con más fuerza - END- Proponen inspeccionar edificios en PR por movimientos de terremotos recientes - El Vocero - Muere la leyenda Matino Clemente - A ciegas para diagnosticar casos de psoriasis en PR - Primera HoraIncluye auspicio

Highly processed vegetable oils, derived from seeds and beans, have become a dominant part of modern diets despite significant health concerns. Historical biases in nutrition science, influenced by the vegetable oil industry, have promoted these oils despite evidence from controlled studies showing negative health outcomes. These oils are unstable, prone to oxidation, and can create toxic byproducts, particularly when exposed to heat, contributing to inflammation and chronic diseases. Although they can lower LDL cholesterol, studies have shown that this reduction does not necessarily improve heart health and may increase risks for other conditions like cancer. In contrast, traditional fats like extra virgin olive oil and omega-3-rich foods offer more stability and health benefits, emphasizing the need for a balanced, minimally processed approach to dietary fats. In this episode, I talk with Nina Teicholz and Max Lugavere to explore the health impacts of different types of fats and oils, debunking misconceptions around cooking with extra virgin olive oil and emphasizing the dangers of industrial vegetable oils. Nina Teicholz is a science journalist and author of the New York Times bestseller, The Big Fat Surprise, which upended the conventional wisdom on dietary fat—especially saturated fat—and spurred a new conversation about whether these fats in fact cause heart disease. She is also the founder of the Nutrition Coalition, a non-profit working to ensure that government nutrition policy is transparent and evidence-based—work for which she's been asked to testify before the U.S. Department of Agriculture and the Canadian Senate. Max Lugavere is a health and science journalist and the author of the New York Times best-seller Genius Foods: Become Smarter, Happier, and More Productive While Protecting Your Brain for Life, now published in 10 languages around the globe. His sophomore book, also a best-seller, is called The Genius Life: Heal Your Mind, Strengthen Your Body, and Become Extraordinary and latest book Genius Kitchen. Max is the host of a #1 iTunes health and wellness podcast, called The Genius Life. Max appears regularly on The Dr. Oz Show, The Rachael Ray Show, and The Doctors. He has contributed to Medscape, Vice, Fast Company, CNN, and The Daily Beast, has been featured on NBC Nightly News, The Today Show, and in The New York Times and People Magazine. He is an internationally sought-after speaker and has given talks at South by Southwest, the New York Academy of Sciences, the Biohacker Summit in Stockholm, Sweden, and many others. Full length episodes can be found here: Is Vegetable Oil Good or Bad for You? Nina Teicholz The Best Diet for Your Brain This episode is brought to you by BIOptimizers. Head to bioptimizers.com/hyman and use code HYMAN10 to save 10%.